Kyle Doherty

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

Zongertinib showed responses across HER2-mutated tumor types, including in lung cancer, with a tolerable safety profile.

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.

Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

ARX788 was safe and effective in HER2+ advanced breast cancer after disease progression on 1 line of a trastuzumab-based regimen.

Thierry André, MD, discusses findings from the phase 3 CheckMate 8HW trial of nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Quizartinib with 7+3 chemotherapy was safe and effective in patients with FLT3-ITD–negative AML, leading to the initiation of the phase 3 QuANTUM-Wild trial.

Tracy I. George, MD, discusses testing considerations in indolent systemic mastocytosis, including the role of serum tryptase and KIT D816V testing.

Multiple myeloma experts offer their perspectives on the evolution of the treatment landscape over the past 10 years and look towards the future of care.

Nirav N. Shah, MD, discusses findings from the phase 2 DALY II USA of zamto-cel in relapsed/refractory DLBCL.

Bradley Muller, MD, discusses how his experience as a patient with cancer led to him working to improve outcomes for the next generation of patients.

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Camizestrant plus a CDK4/6 inhibitor was safe and effective in frontline ESR1-mutated HR-positive/HER2-negative advanced breast cancer.

Faculty at Hackensack Meridian School of Medicine developed a novel curriculum to improve medical training through practical, clinic-focused learning.

OH2 monotherapy was safe and treatment with the agent led to responses in combination with HX008 in locally advanced or metastatic sarcoma.

During the whirlwind of emotions and obligations brought on by a cancer diagnosis, the sexual health needs of patients are often overlooked by clinicians.

The long-acting IL-7 agent efineptakin alfa was tolerable and led to responses in patients with Kaposi sarcoma, including in HIV-associated disease.

Noam E. Shabani, MS, PA-C, director of the Dana-Farber Postgraduate PA Oncology Fellowship highlights the program and its impact on improved access to care for patients.

The HyperVIEW X-ray system has received breakthrough device designation from the FDA for contrast-enhanced imaging for diagnosis of breast cancer.

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

The Christie NHS Foundation Trust has created a supportive oncology program to train fellows and offer services for patients living with cancer.

Alisertib plus ibrutinib and rituximab showed antitumor activity in mantle cell lymphoma in a preclinical study.

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

A chatbot-based approach was equivalent to SOC pretest cancer genetic services and genetic testing among individuals eligible for cancer genetic testing.